請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5352
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡孟君(Meng-Chun Hu) | |
dc.contributor.author | Yuan-Ching Chang | en |
dc.contributor.author | 張源清 | zh_TW |
dc.date.accessioned | 2021-05-15T17:56:38Z | - |
dc.date.available | 2016-10-09 | |
dc.date.available | 2021-05-15T17:56:38Z | - |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-06-25 | |
dc.identifier.citation | 1. Ferlay, J., et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010. 127(12): p. 2893-917.
2. Anderson, B.O., et al., Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer, 2008. 113(8 Suppl): p. 2221-43. 3. Anderson, B.O., et al., Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol, 2011. 12(4): p. 387-98. 4. Lin, C.H., et al., The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer, 2012. 130(11): p. 2629-37. 5. Ziegler, R.G., et al., Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst, 1993. 85(22): p. 1819-27. 6. Shin, H.R., et al., Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control, 2010. 21(11): p. 1777-85. 7. Jung, K.W., et al., Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat, 2013. 45(1): p. 15-21. 8. Land, C.E., et al., Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res, 2003. 160(6): p. 707-17. 9. London, S.J., et al., A prospective study of benign breast disease and the risk of breast cancer. JAMA, 1992. 267(7): p. 941-4. 10. Fisher, B., et al., Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 2005. 97(22): p. 1652-62. 11. Martino, S., et al., Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst, 2004. 96(23): p. 1751-61. 12. Goss, P.E., et al., Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med, 2011. 364(25): p. 2381-91. 13. Cuzick, J., et al., Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst, 2007. 99(4): p. 272-82. 14. Colditz, G.A. and B. Rosner, Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol, 2000. 152(10): p. 950-64. 15. Witton, C.J., et al., Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 2003. 200(3): p. 290-7. 16. Nahta, R. and F.J. Esteva, Herceptin: mechanisms of action and resistance. Cancer Lett, 2006. 232(2): p. 123-38. 17. Wong, H., et al., Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2(+) metastatic breast cancer. Oncologist, 2011. 16(11): p. 1535-46. 18. Baselga, J., Treatment of HER2-overexpressing breast cancer. Ann Oncol, 2010. 21 Suppl 7: p. 36-40. 19. O'Donovan, N., et al., Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest New Drugs, 2011. 29(5): p. 752-9. 20. Verma, S., et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 2012. 367(19): p. 1783-91. 21. Malloy, K.M. and M.F. Cunnane, Pathology and cytologic features of thyroid neoplasms. Surg Oncol Clin N Am, 2008. 17(1): p. 57-70. 22. Lang, B.H., et al., Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg, 2007. 245(3): p. 366-78. 23. Morris, L.G. and D. Myssiorek, Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg, 2010. 200(4): p. 454-61. 24. Hundahl, S.A., et al., A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 1998. 83(12): p. 2638-48. 25. Are, C. and A.R. Shaha, Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol, 2006. 13(4): p. 453-64. 26. Fritze, D. and G.M. Doherty, Surgical management of cervical lymph nodes in differentiated thyroid cancer. Otolaryngol Clin North Am, 2010. 43(2): p. 285-300. 27. Lundgren, C.I., et al., Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer, 2006. 106(3): p. 524-31. 28. Kilfoy, B.A., et al., International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control, 2009. 20(5): p. 525-31. 29. Cramer, J.D., et al., Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery, 2010. 148(6): p. 1147-52. 30. Mazzaferri, E.L. and R.T. Kloos, Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 2001. 86(4): p. 1447-63. 31. Shakhar, G. and S. Ben-Eliyahu, Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol, 2003. 10(8): p. 972-92. 32. Fidler, I.J., The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer, 2003. 3(6): p. 453-8. 33. Langley, R.R. and I.J. Fidler, Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev, 2007. 28(3): p. 297-321. 34. Valastyan, S. and R.A. Weinberg, Tumor metastasis: molecular insights and evolving paradigms. Cell, 2011. 147(2): p. 275-92. 35. Gupta, G.P. and J. Massague, Cancer metastasis: building a framework. Cell, 2006. 127(4): p. 679-95. 36. Steeg, P.S., Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 2006. 12(8): p. 895-904. 37. Yamaguchi, K., et al., Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg, 2000. 232(1): p. 58-65. 38. Biki, B., et al., Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology, 2008. 109(2): p. 180-7. 39. Buggy, D.J. and G. Smith, Epidural anaesthesia and analgesia: better outcome after major surgery?. Growing evidence suggests so. BMJ, 1999. 319(7209): p. 530-1. 40. Coffey, J.C., et al., Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol, 2003. 4(12): p. 760-8. 41. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74. 42. Tsuchiya, Y., et al., Increased surgical stress promotes tumor metastasis. Surgery, 2003. 133(5): p. 547-55. 43. Lacy, A.M., et al., Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet, 2002. 359(9325): p. 2224-9. 44. Vittimberga, F.J., Jr., et al., Laparoscopic surgery and the systemic immune response. Ann Surg, 1998. 227(3): p. 326-34. 45. Markovic, S.N., P.R. Knight, and D.M. Murasko, Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology, 1993. 78(4): p. 700-6. 46. Mitsuhata, H., R. Shimizu, and M.M. Yokoyama, Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol, 1995. 17(6): p. 529-34. 47. Schlagenhauff, B., et al., Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res, 2000. 10(2): p. 165-9. 48. Exadaktylos, A.K., et al., Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology, 2006. 105(4): p. 660-4. 49. Brand, J.M., et al., The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin Immunol Immunopathol, 1997. 83(2): p. 190-4. 50. Sessler, D.I., Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev, 2008. 17(3): p. 269-72. 51. Vallejo, R., O. de Leon-Casasola, and R. Benyamin, Opioid therapy and immunosuppression: a review. Am J Ther, 2004. 11(5): p. 354-65. 52. Beilin, B., et al., Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats. Brain Behav Immun, 1989. 3(2): p. 129-37. 53. Gupta, K., et al., Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res, 2002. 62(15): p. 4491-8. 54. Beilin, B., et al., Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg, 1996. 82(3): p. 492-7. 55. Yeager, M.P., et al., Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology, 1995. 83(3): p. 500-8. 56. Johnson, S.M., B.E. Saint John, and A.P. Dine, Local anesthetics as antimicrobial agents: a review. Surg Infect (Larchmt), 2008. 9(2): p. 205-13. 57. Borgeat, A. and J. Aguirre, Update on local anesthetics. Curr Opin Anaesthesiol, 2010. 23(4): p. 466-71. 58. Piper, S.L., et al., Effects of local anesthetics on articular cartilage. Am J Sports Med, 2011. 39(10): p. 2245-53. 59. Villar-Garea, A., et al., Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res, 2003. 63(16): p. 4984-9. 60. Sakaguchi, M., Y. Kuroda, and M. Hirose, The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg, 2006. 102(4): p. 1103-7. 61. Piegeler, T., et al., Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade. Anesthesiology, 2012. 117(3): p. 548-59. 62. Lirk, P., et al., In vitro, inhibition of mitogen-activated protein kinase pathways protects against bupivacaine- and ropivacaine-induced neurotoxicity. Anesth Analg, 2008. 106(5): p. 1456-64, table of contents. 63. Lu, J., et al., Bupivacaine induces apoptosis via mitochondria and p38 MAPK dependent pathways. Eur J Pharmacol, 2011. 657(1-3): p. 51-8. 64. Mammoto, T., et al., Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). J Cell Physiol, 2002. 192(3): p. 351-8. 65. Tada, M., et al., Procaine inhibits the proliferation and DNA methylation in human hepatoma cells. Hepatol Int, 2007. 1(3): p. 355-64. 66. Perez-Castro, R., et al., Cytotoxicity of local anesthetics in human neuronal cells. Anesth Analg, 2009. 108(3): p. 997-1007. 67. Sidiropoulou, T., et al., A prospective comparison of continuous wound infiltration with ropivacaine versus single-injection paravertebral block after modified radical mastectomy. Anesth Analg, 2008. 106(3): p. 997-1001. 68. Albi-Feldzer, A., et al., A double-blind randomized trial of wound and intercostal space infiltration with ropivacaine during breast cancer surgery: effects on chronic postoperative pain. Anesthesiology, 2013. 118(2): p. 318-26. 69. American Thyroid Association Guidelines Taskforce on Thyroid, N., et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009. 19(11): p. 1167-214. 70. Lewis, B.D., et al., Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol, 2002. 178(3): p. 699-704. 71. Monchik, J.M., et al., Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg, 2006. 244(2): p. 296-304. 72. Baek, J.H., et al., Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol, 2011. 197(2): p. 331-6. 73. Shin, J.E., J.H. Baek, and J.H. Lee, Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol, 2013. 25(1): p. 14-9. 74. Schweppe, R.E., et al., Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab, 2008. 93(11): p. 4331-41. 75. Cheng, S.P., et al., Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep, 2011. 26(5): p. 1265-71. 76. Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 2006. 58(3): p. 621-81. 77. Cheng, S.P., et al., Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep, 2010. 23(6): p. 1721-7. 78. Cheng, S.P., et al., Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys, 2013. 65(2): p. 203-10. 79. Engels, I.H., et al., Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol, 2005. 25(7): p. 2808-18. 80. Janicke, R.U., et al., Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem, 1998. 273(16): p. 9357-60. 81. Werdehausen, R., et al., Apoptosis induction by different local anaesthetics in a neuroblastoma cell line. Br J Anaesth, 2009. 103(5): p. 711-8. 82. Yoon, J.R., et al., Local anesthetics inhibit kinesin motility and microtentacle protrusions in human epithelial and breast tumor cells. Breast Cancer Res Treat, 2011. 129(3): p. 691-701. 83. Garib, V., et al., Influence of non-volatile anesthetics on the migration behavior of the human breast cancer cell line MDA-MB-468. Acta Anaesthesiol Scand, 2002. 46(7): p. 836-44. 84. Snyder, G.L. and S. Greenberg, Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth, 2010. 105(2): p. 106-15. 85. Esposito, M., et al., Improved therapeutic index of cisplatin by procaine hydrochloride. J Natl Cancer Inst, 1990. 82(8): p. 677-84. 86. Arai, Y., et al., Enhancement of hyperthermia-induced apoptosis by local anesthetics on human histiocytic lymphoma U937 cells. J Biol Chem, 2002. 277(21): p. 18986-93. 87. Zwischenberger, J.B., et al., Percutaneous venovenous perfusion-induced systemic hyperthermia for lung cancer: a phase I safety study. Ann Thorac Surg, 2004. 77(6): p. 1916-24. 88. Sakura, S., et al., Local anesthetic neurotoxicity does not result from blockade of voltage-gated sodium channels. Anesth Analg, 1995. 81(2): p. 338-46. 89. Hirata, M., et al., Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells. Anesthesiology, 2004. 100(5): p. 1206-10. 90. Lostumbo, A., et al., Flow cytometry: a new approach for the molecular profiling of breast cancer. Exp Mol Pathol, 2006. 80(1): p. 46-53. 91. Esteller, M., Relevance of DNA methylation in the management of cancer. Lancet Oncol, 2003. 4(6): p. 351-8. 92. Villar-Garea, A. and M. Esteller, DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr Drug Metab, 2003. 4(1): p. 11-31. 93. Lirk, P., et al., Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro. Br J Anaesth, 2012. 109(2): p. 200-7. 94. Sprick, M.R., et al., Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J, 2002. 21(17): p. 4520-30. 95. Gottschalk, A., et al., Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg, 2010. 110(6): p. 1636-43. 96. Herroeder, S., et al., Systemic lidocaine shortens length of hospital stay after colorectal surgery: a double-blinded, randomized, placebo-controlled trial. Ann Surg, 2007. 246(2): p. 192-200. 97. Page, G.G., W.P. Blakely, and S. Ben-Eliyahu, Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain, 2001. 90(1-2): p. 191-9. 98. Bar-Yosef, S., et al., Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology, 2001. 94(6): p. 1066-73. 99. McCarthy, G.C., S.A. Megalla, and A.S. Habib, Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from surgery: a systematic review of randomized controlled trials. Drugs, 2010. 70(9): p. 1149-63. 100. Grigoras, A., et al., Perioperative intravenous lidocaine decreases the incidence of persistent pain after breast surgery. Clin J Pain, 2012. 28(7): p. 567-72. 101. Drasner, K., Lidocaine spinal anesthesia: a vanishing therapeutic index? Anesthesiology, 1997. 87(3): p. 469-72. 102. Friederich, P. and T.P. Schmitz, Lidocaine-induced cell death in a human model of neuronal apoptosis. Eur J Anaesthesiol, 2002. 19(8): p. 564-70. 103. Lee, H.T., et al., Local anesthetics induce human renal cell apoptosis. Am J Nephrol, 2003. 23(3): p. 129-39. 104. Kawasaki, C., et al., Lidocaine enhances apoptosis and suppresses mitochondrial functions of human neutrophil in vitro. J Trauma, 2010. 68(2): p. 401-8. 105. Kamiya, Y., K. Ohta, and Y. Kaneko, Lidocaine-induced apoptosis and necrosis in U937 cells depending on its dosage. Biomed Res, 2005. 26(6): p. 231-9. 106. Werdehausen, R., et al., Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. Anesthesiology, 2007. 107(1): p. 136-43. 107. Eguchi, Y., S. Shimizu, and Y. Tsujimoto, Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res, 1997. 57(10): p. 1835-40. 108. Jain, M.V., et al., Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med, 2013. 17(1): p. 12-29. 109. Karniel, M. and R. Beitner, Local anesthetics induce a decrease in the levels of glucose 1, 6-bisphosphate, fructose 1,6-bisphosphate, and ATP, and in the viability of melanoma cells. Mol Genet Metab, 2000. 69(1): p. 40-5. 110. Grouselle, M., et al., Effect of local anaesthetics on mitochondrial membrane potential in living cells. Biochem J, 1990. 271(1): p. 269-72. 111. Irwin, W., et al., Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem, 2002. 277(14): p. 12221-7. 112. Nouette-Gaulain, K., et al., From analgesia to myopathy: When local anesthetics impair the mitochondrion. Int J Biochem Cell Biol, 2011. 43(1): p. 14-9. 113. Cela, O., et al., Bupivacaine uncouples the mitochondrial oxidative phosphorylation, inhibits respiratory chain complexes I and III and enhances ROS production: results of a study on cell cultures. Mitochondrion, 2010. 10(5): p. 487-96. 114. Cairns, R.A., I.S. Harris, and T.W. Mak, Regulation of cancer cell metabolism. Nat Rev Cancer, 2011. 11(2): p. 85-95. 115. Unami, A., et al., Biochemical and microarray analyses of bupivacaine-induced apoptosis. J Toxicol Sci, 2003. 28(2): p. 77-94. 116. Lucchinetti, E., et al., Antiproliferative effects of local anesthetics on mesenchymal stem cells: potential implications for tumor spreading and wound healing. Anesthesiology, 2012. 116(4): p. 841-56. 117. Lirk, P., et al., In vitro, lidocaine-induced axonal injury is prevented by peripheral inhibition of the p38 mitogen-activated protein kinase, but not by inhibiting caspase activity. Anesth Analg, 2007. 105(6): p. 1657-64. 118. Harato, M., et al., Bupivacaine-induced apoptosis independently of WDR35 expression in mouse neuroblastoma Neuro2a cells. BMC Neurosci, 2012. 13: p. 149. 119. Wagner, E.F. and A.R. Nebreda, Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer, 2009. 9(8): p. 537-49. 120. Pomerance, M., et al., High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J Pathol, 2006. 209(3): p. 298-306. 121. Joo, J.D., et al., Lidocaine suppresses the increased extracellular signal-regulated kinase/cyclic AMP response element-binding protein pathway and pro-inflammatory cytokines in a neuropathic pain model of rats. Eur J Anaesthesiol, 2011. 28(2): p. 106-11. 122. Wang, Z., et al., Lithium attenuates bupivacaine-induced neurotoxicity in vitro through phosphatidylinositol-3-kinase/threonine-serine protein kinase B- and extracellular signal-regulated kinase-dependent mechanisms. Neuroscience, 2012. 206: p. 190-200. 123. Junttila, M.R., S.P. Li, and J. Westermarck, Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J, 2008. 22(4): p. 954-65. 124. Xing, M., Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 2013. 13(3): p. 184-99. 125. Leboeuf, R., et al., BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab, 2008. 93(6): p. 2194-201. 126. Fried, I.A., The influence of the anaesthetic on survival rates of breast cancer patients after surgery. Int J Cancer, 1977. 20(2): p. 213-8. 127. Siddiqui, R.A., et al., Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res, 2005. 7(5): p. 645-54. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5352 | - |
dc.description.abstract | 乳癌對女性健康和精神方面一直是莫大的威脅。佔台灣青壯年(30~60歲)女性癌症發生率第一位。值得注意的是,台灣地區婦女乳癌症發生率有逐年升高的趨勢。另外甲狀腺癌的發生率近年來也有顯著增加。外科手術仍是乳癌、甲狀腺癌治療中之極重要一環。吸入性氣體麻醉全身麻醉在接受手術的病人上可能有術後疼痛及噁心、嘔吐的副作用。手術創傷也會引起不當免疫反應,而免疫缺損則可能促成腫瘤生長和擴散。局部麻醉可以阻止外科手術創傷訊息傳入,已經廣泛應用於癌症診斷切片和細胞抽吸。近來更可使用局部麻醉藥品在鎮靜麻醉下應用於乳癌手術。
本研究使用之局部麻醉藥品(Lidocaine, Bupivacaine) 以乳癌腫瘤、甲狀腺癌細胞和利用腫瘤之動物模式,發現其對腫瘤細胞抑制的效果。 本研究發現局部麻醉藥品以低於臨床乳癌手術使用的局部麻醉劑量,影響粒腺體和胞外凋亡路徑而導致的凋亡蛋白酶7,8,9活化,就會造成乳癌細胞的死亡,而對正常乳腺細胞株較無影響。 另外也發現局部麻醉藥品能抑制甲狀腺癌腫瘤細胞的生存能力,減少細胞群落形成。藉由瓦解粒線體膜電位,釋放细胞色素C (Cytochrome C),活化凋亡蛋白酶3,7,升高Bax/Bcl-2比例進而引發甲狀腺癌細胞凋亡及壞死。由局部麻醉藥品所誘導之MAPK訊息傳遞路徑可能為其促進細胞凋亡之重要機轉。 總結來說,本研究發現局部麻醉劑的抑制癌細胞效果。我們大膽預測,本研究的延伸可能帶來醫界重大的衝擊,提供兼顧腫瘤控制的乳癌和甲狀腺癌手術麻醉模式。 | zh_TW |
dc.description.abstract | The incidence of breast and thyroid cancer has remarkably increased in recent years. Local anesthetics are frequently used in fine-needle aspiration of thyroid lesions and locoregional control of persistent or recurrent thyroid cancer. Wound infiltration with local anesthetics reduces postoperative pain after breast surgery. Recent evidence suggests that local anesthetics have a broad spectrum of effects including inhibition of cell proliferation and induction of apoptosis in neuronal and other types of cells.
In this study, we demonstrated that treatment with lidocaine and bupivacaine resulted in decreased cell viability and colony formation of both 8505C and K1 cells in a dose-dependent manner. Lidocaine and bupivacaine induced apoptosis, and necrosis in high concentrations, as determined by flow cytometry. Lidocaine and bupivacaine caused disruption of mitochondrial membrane potential and release of cytochrome c, accompanied by activation of caspase 3 and 7, PARP cleavage, and induction of a higher ratio of Bax/Bcl-2. Based on microarray and pathway analysis, apoptosis is the prominent transcriptional change common to lidocaine and bupivacaine treatment. Furthermore, lidocaine and bupivacaine attenuated extracellular signal-regulated kinase 1/2 (ERK1/2) activity and induced activation of p38 mitogen-activated protein kinase (MAPK) and c-jun N-terminal kinase. Pharmacological inhibitors of MAPK/ERK kinase and p38 MAPK suppressed caspase 3 activation and PARP cleavage. Taken together, our results for the first time demonstrate the cytotoxic effects of local anesthetics on thyroid cancer cells and implicate the MAPK pathways as an important mechanism. We also demonstrated that the apoptotic effects of local anesthetics in human breast tumor cells. Treatment of breast tumor cells with lidocaine and bupivacaine at clinically relevant concentrations resulted in inhibition of cell viability via induction of apoptosis. The effects were more prominent in MCF-7 cells than in MCF-10A cells. Treatment with local anesthetics induced caspase 7, 8, 9, and poly ADP-ribose polymerase (PARP) cleavage. The cleavage of caspase 7 and PARP induced by local anesthetics was effectively blocked by caspase inhibitors. Furthermore, treatment of MCF-7 xenografts with local anesthetics resulted in higher expression of cleaved caspase 7 and an increase in terminal deoxynucleotidyl transferase dUTP nick-end labeling staining. Our findings reveal previously unrecognized beneficial actions of local anesthetics and call for further studies to assess the oncologic advantages of their use during breast cancer surgery and in the management of patients with thyroid cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:56:38Z (GMT). No. of bitstreams: 1 ntu-103-D96441002-1.pdf: 3519321 bytes, checksum: fc7f1bafc150fbb2de7259a26065d9c7 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要..................................................iii
Abstrac...................................................iv Acronyms and Abbreviations................................vi Introduction...............................................1 Breast cancer..............................................1 Thyroid cancer.............................................7 Effect of anesthetic technique and surgery on Cancer Recurrence.................................................9 Dark side of oncological surgery..........................11 Effect of anesthesia on cancer recurrence.................13 Role of local anesthetics in breast cancer surgery........14 Role of local anesthetics in thyroid cancer surgery.......15 Aims of the Study.........................................16 Materials and Methods.....................................17 Results...................................................26 Effects of lidocaine and bupivacaine on breast tumor cell viability.................................................26 Induction of breast cancer cell apoptosis.................26 Caspase activation induced by lidocaine and bupivacaine...27 Effects of Caspase Inhibitors on breast tumor cells.......28 Effects in xenograft breast tumors........................28 Inhibition of thyroid tumor cell growth and colony formation.................................................29 Induction of thyroid cancer cell apoptosis................30 Assessment of mitochondrial dysfunction...................30 Activation of caspases by local anesthetics...............31 Analysis of gene expression signatures affected by local anesthetics...............................................32 Modulation of mitogen-activated protein kinase signaling.................................................32 Effects of inhibition of mitogen-activated protein kinases...................................................33 Discussion................................................34 Conclusion................................................39 Future perspective........................................40 References................................................44 Tables....................................................53 Figures...................................................55 Supporting information....................................80 Appendix..................................................81 | |
dc.language.iso | en | |
dc.title | 局部麻醉藥劑促進腫瘤細胞凋亡之研究 | zh_TW |
dc.title | Apoptosis Induced by Local Anesthetics in Tumor Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張丞圭(Cheng-Kuei Chang),黃俊升(Chium-Sheng Huang),曾令民(Ling-Ming Tseng),賴亮全(Liang-chuan Lai) | |
dc.subject.keyword | 乳癌,甲狀腺癌,麻醉,局部麻醉劑,細胞凋亡, | zh_TW |
dc.subject.keyword | breast cancer,thyroid cancer,local anesthetics,anesthesia,apoptosis, | en |
dc.relation.page | 82 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-06-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 3.44 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。